We’re starting a monthly newsletter to help you keep on top of the best news articles about biopharma partnerships. Stay up-to-date with these articles, which feature exciting breakthrough discoveries, interesting collaborations, biopharma trends and smart strategies. The first of these newsletters is below.
To receive your own copy of the Inova Top 10 Newsletter sign up here. You’ll get the most valuable biopharma partnerships articles sent straight to your inbox, once a month, every month.
Discover the story of James Allison. His research led to the development of Yervoy, an immunotherapy treatment for metastatic melanoma by Bristol-Myers Squibb. He was the first researcher to realize that the body’s immune system could be turbocharged to fight cancer.
Check out this white paper by QuintilesIMS. It analyzes the choices that must be made by emerging biopharma companies preparing to launch their first product. Is it in their interest to go it alone or partner with big pharma? What does that mean for large pharma companies looking for partnerships?
Pieris Pharmaceuticals is on a roll! For their protein engineering work, they’ve just signed a hefty partnership with AstraZeneca, featuring a large upfront payment and millions in milestones down the road. This deal comes on the heels of another large pact Pieris signed with Servier just 4 months ago.
Alphabet is looking to make its mark in the life sciences and is working a multi-pronged approached. For example, Alphabet has both biotech companies that it has invested in directly as well as a venture capital arm that invests in early-stage life science start-ups. Learn more about their efforts.
Bruce Levine is an innovator known for his work in developing synthetic immune cells that attack advanced cancer cells. Although his research was groundbreaking, finding funding and partners was still difficult. The FDA has now granted Breakthrough Therapy designations for several drug applications developed by Levine and Novartis.
Take a closer look at recent complete response letters (CRLs) trends. In 2016, the FDA issued an unusually high number of CRLs, often citing manufacturing issues. This has put a strain on drug developer/CMO partnerships, forcing drug developers to be more vigilant about their partners’ practices.
Things are looking up for the biopharma industry. The FDA has already approved 20 new drugs this year– a much better pace compared to last year. Additionally, quite a few of these new drugs are first-ever treatments for certain diseases, making them important breakthroughs for patients.
Learn about trends in drug delivery innovation from experts at Merck and Boehringer Ingelheim. Innovative drug delivery not only enhances and extends the value of treatments, but it also solves problems created by new drug complexity. Partners play a key role by providing additional resources and expertise.
Clinical trials are expensive. Some biopharma companies are reducing costs by partnering with CROs, universities, and patient advocacy organizations to fund trials. This article covers five steps for assessing whether this type of partnership is feasible for your company and how to make it happen.
Ending on an especially inspirational note, read the story of a young woman saved by an innovative clinical trial at Johns Hopkins. Based on this clinical trial, the FDA has, for the first time, approved a cancer treatment based on the genetic characteristics of the tumor, instead of its location. The idea for this treatment is the result of a brainstorm between cancer researchers and geneticists at Hopkins.